Current Report Filing (8-k)
December 28 2016 - 4:37PM
Edgar (US Regulatory)
United
States Securities And Exchange Commission
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 22, 2016
ISORAY, INC.
(Exact name of registrant as specified in
its charter)
Minnesota
(State or other jurisdiction
of incorporation)
|
001-33407
(Commission
File Number)
|
41-1458152
(IRS Employer
Identification No.)
|
350 Hills Street, Suite 106, Richland,
Washington 99354
(Address of principal executive offices)
(Zip Code)
(509) 375-1202
(Registrant’s telephone number)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
¨
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
¨
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
¨
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
ITEM 1.01
|
Entry into a Material
Definitive Agreement
|
On December 22, 2016,
IsoRay Medical, Inc. (“Medical”), a wholly owned subsidiary of IsoRay, Inc. (the “Registrant”), entered
into Addendum No. 1 (the “Addendum”) to its supply contract (the “Agreement”) with The Open Joint Stock
Company ‹‹Isotope››, a Russian company (“JSC Isotope”). With the Addendum, Medical will
purchase Cesium-131 manufactured by Joint Stock Company ‹‹Institute of Nuclear Materials›› and sold
by JSC Isotope, within the quality standards and within the time periods specified, through December 31, 2017 rather than March
31, 2017 as provided in the Agreement.
|
ITEM 9.01
|
Financial Statements and Exhibits
|
|
10.1
|
Addendum No. 1 to Contract, dated December 22, 2016 and effective as of December 9, 2016, by and between IsoRay Medical, Inc. and The Open Joint Stock Company ‹‹ Isotope ›› (confidential treatment requested for redacted portions)
|
SIGNATURES
In accordance with
the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
Dated: December 28, 2016
|
|
|
|
|
|
|
|
|
IsoRay, Inc., a Minnesota corporation
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Brien Ragle
|
|
|
|
Brien Ragle, CFO
|
|
IsoRay (AMEX:ISR)
Historical Stock Chart
From Jul 2024 to Aug 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Aug 2023 to Aug 2024